New launches which have the potential to cumulatively generate greater than €30 billion over the first five years of sales, Sanofi outlines at an IR Thematic Seminar on New Medicines its intention to launch high-potential new medicines and vaccines that could result in upto 18 new launches for the company between 2014-2020.

This will confirm the strong momentum of the company’s R&D pipeline and ability to deliver new therapies across a range of therapeutic categories.

“These potential launches affirm Sanofi’s strategy, which has been in place since 2008, and clearly demonstrate the strong momentum of Sanofi’s R&D pipeline,” said Serge Weinberg, Chairman of the Board and CEO, Sanofi. “As we move into this period of successive new product launches, we are investing in launch excellence and execution while continuing to fuel innovation to grow our existing pipeline.”

Sanofi’s seminar will consist of presentations on nine new medicines and vaccines in segments like rare diseases - multiple sclerosis, cardiovascular disease, diabetes, vaccine for dengue, immunology and inflammation.


“Sanofi’s global R&D teams have created an impressive dynamic that leverages internal talents and open innovation to develop an industry-leading pipeline,” said Elias Zerhouni, MD, president, global research and development, Sanofi. “Sanofi has the potential to launch up to six new medicines in 2015 and approximately one new medicine every six months between 2016 and 2018. These new medicines have the potential to help address significant areas of need in rare diseases, cardiovascular care, diabetes, immunology and public health.”

The presentation in Boston will demonstrate Sanofi’s opportunity to generate sustainable growth driven by the solid momentum of its growth platforms and the expected accelerated sales contribution of its late-stage R&D pipeline. In diabetes, despite the potential impact of the US basal insulin market dynamics on Lantus sales, Sanofi expects its global diabetes sales to be flat to slightly growing from 2015 – 2018.

This assumes a substantial conversion of patients from Lantus to Toujeo in the US and Europe, continued growth of its diabetes products in emerging markets, the US launches of Affreza, Lyxumia and LixiLan. The launch of new medicines and vaccines in other therapeutic areas and the sustained performance of Sanofi’s other growth platforms is expected to continue to further reduce the relative contribution of Lantus to the Group's overall performance.